Interferon alfa-2a: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Protected "Interferon alfa-2a": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(4 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
{{DrugProjectFormSinglePage
{{Interferon alfa-2a}}
|authorTag={{RB}}
{{CMG}}
|genericName=Interferon alfa-2a
|aOrAn=a
|drugClass=antiviral
|indicationType=treatment
|indication=RECURRENT VIRAL INFECTIONS
|adverseReactions=[[Melena|black stools]], [[chills]], [[cough]], [[fever]], [[irritability]]


==Overview==
'''[[Pegylated]] [[interferon]] alfa-2a''' (pegylated with a branched 40 kDa PEG chain; commercial name '''Pegasys''') is an [[antiviral drug]] discovered at the pharmaceutical company [[Hoffmann-La Roche|F. Hoffmann-La Roche]]; it has a dual mode of action - both antiviral and on the immune system. The addition of [[polyethylene glycol]] to the interferon, through a process known as [[pegylation]], enhances the [[Biological half-life|half-life]] of the interferon when compared to its native form.


==Category==
Antiviral


==US Brand Names==
<!--Black Box Warning-->
ROFERON-A<sup>®</sup>,PEGASYS<sup>®</sup>,GUNA-INF ALPHA<sup>®</sup>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>


==FDA Package Insert==


'''  [[Interferon alfa-2a description|Description]]'''
'''| [[Interferon alfa-2a clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Interferon alfa-2a microbiology|Microbiology]]'''
'''| [[Interferon alfa-2a indications and usage|Indications and Usage]]'''
'''| [[Interferon alfa-2a contraindications|Contraindications]]'''
'''| [[Interferon alfa-2a warnings and precautions|Warnings and Precautions]]'''
'''| [[Interferon alfa-2a adverse reactions|Adverse Reactions]]'''
'''| [[Interferon alfa-2a drug interactions|Drug Interactions]]'''
'''| [[Interferon alfa-2a overdosage|Overdosage]]'''
'''| [[Interferon alfa-2a clinical studies|Clinical Studies]]'''
'''| [[Interferon alfa-2a dosage and administration|Dosage and Administration]]'''
'''| [[Interferon alfa-2a how supplied|How Supplied]]'''
'''| [[Interferon alfa-2a labels and packages|Labels and Packages]]'''


==Mechanism of Action==
<!--Adult Indications and Dosage-->
The mechanism by which Interferon alfa-2a, recombinant, or any other interferon, exerts antitumor or antiviral activity is not clearly understood. However, it is believed that direct antiproliferative action against tumor cells, inhibition of virus replication and modulation of the host immune response play important roles in antitumor and antiviral activity.


==References==
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult=====Indications====
* RECURRENT VIRAL INFECTIONS


{{Reflist|2}}
====Directions====
* Take 15 minutes before meals.
* Adults and children 12 years and older : 20 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


[[Category:Antibiotics]]
<!--Non–Guideline-Supported Use (Adult)-->
[[Category:Wikinfect]]
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed=====Indications====
RECURRENT VIRAL INFECTIONS
 
====Directions====
* Children  between 12 years and 6 years of age: 10 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow.
* Children under 6 years: 5 drops twice a day in a glass of water.
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
|contraindications=
 
<!--Warnings-->
|warnings=* Stop use and ask doctor if symptoms worsen or persist more than 3 days
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
 
<!--Postmarketing Experience-->
|postmarketing=[[Melena|black stools]], [[chills]], [[cough]], [[fever]], [[irritability]]
|drugInteractions=
 
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
|administration=* [[Oral]]
 
 
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
 
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
|overdose=There is limited information regarding <i>Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|mechAction=
 
<!--Structure-->
|structure=* ACTIVE INGREDIENT
: INTERFERON ALFA-2A      4C
* INACTIVE INGREDIENT
: Ethyl Alcohol 30%
 
 
 
<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
|howSupplied=
|packLabel=====PRINCIPAL DISPLAY PANEL====
: [[File:Inter PDP.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
====Ingredients and Appearance====
: [[File:Inter I n A.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
 
<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
<!--Precautions with Alcohol-->
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
<!--Brand Names-->
|brandNames=* GUNA-INF ALPHA®<ref>{{Cite web | title = Interferon alfa-2a | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f96495b5-1ffe-432c-adcf-b2db9cfd1405}}</ref>
 
<!--Look-Alike Drug Names-->
|lookAlike=There is limited information regarding the look alike drug names.
|drugShortage=
}}
 
 
<!--Category-->
 
[[Category:Drug]]

Latest revision as of 16:31, 20 August 2015

Interferon alfa-2a
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Interferon alfa-2a is a antiviral that is FDA approved for the treatment of RECURRENT VIRAL INFECTIONS. Common adverse reactions include black stools, chills, cough, fever, irritability.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

  • RECURRENT VIRAL INFECTIONS

Directions

  • Take 15 minutes before meals.
  • Adults and children 12 years and older : 20 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Interferon alfa-2a in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Interferon alfa-2a in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Indications

RECURRENT VIRAL INFECTIONS

Directions

  • Children between 12 years and 6 years of age: 10 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow.
  • Children under 6 years: 5 drops twice a day in a glass of water.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Interferon alfa-2a in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Interferon alfa-2a in pediatric patients.

Contraindications

There is limited information regarding Interferon alfa-2a Contraindications in the drug label.

Warnings

  • Stop use and ask doctor if symptoms worsen or persist more than 3 days

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Interferon alfa-2a in the drug label.

Postmarketing Experience

black stools, chills, cough, fever, irritability

Drug Interactions

There is limited information regarding Interferon alfa-2a Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Interferon alfa-2a in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Interferon alfa-2a during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Interferon alfa-2a with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Interferon alfa-2a with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Interferon alfa-2a with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Interferon alfa-2a with respect to specific gender populations.

Race

There is no FDA guidance on the use of Interferon alfa-2a with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Interferon alfa-2a in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Interferon alfa-2a in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Interferon alfa-2a in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Interferon alfa-2a in patients who are immunocompromised.

Administration and Monitoring

Administration

Monitoring

There is limited information regarding Monitoring of Interferon alfa-2a in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Interferon alfa-2a in the drug label.

Overdosage

There is limited information regarding Overdose of Interferon alfa-2a in the drug label.

Pharmacology

There is limited information regarding Interferon alfa-2a Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Interferon alfa-2a Mechanism of Action in the drug label.

Structure

  • ACTIVE INGREDIENT
INTERFERON ALFA-2A 4C
  • INACTIVE INGREDIENT
Ethyl Alcohol 30%

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Interferon alfa-2a in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Interferon alfa-2a in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Interferon alfa-2a in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Interferon alfa-2a in the drug label.

How Supplied

There is limited information regarding Interferon alfa-2a How Supplied in the drug label.

Storage

There is limited information regarding Interferon alfa-2a Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Interferon alfa-2a |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

PRINCIPAL DISPLAY PANEL

This image is provided by the National Library of Medicine.

Ingredients and Appearance

This image is provided by the National Library of Medicine.

{{#ask: Label Page::Interferon alfa-2a |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Interferon alfa-2a in the drug label.

Precautions with Alcohol

  • Alcohol-Interferon alfa-2a interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • GUNA-INF ALPHA®[1]

Look-Alike Drug Names

There is limited information regarding the look alike drug names.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ "Interferon alfa-2a".
Retrieved from "https://www.wikidoc.org/index.php?title=Interferon_alfa-2a&oldid=1136835"